Monday, April 4, 2011

Nile wins fast-track status for heart drug

Nile Therapeutics Inc. won fast-track designation from the Food and Drug Administration for its drug to treat acute decompensated heart failure patients after they leave the hospital.
The San Mateo company (NASDAQ: NLTX) plans to develop the drug, called cenderitide, for use up to 90 days after patients are discharged from a hospital. There is no drug approved for that so-called post-acute indication, with most patients now typically sent home with water pills or nitroglycerin tablets and nearly a third of patients returning to the hospital after a cardiac event within 90 days.

No comments:

Post a Comment